Almirall’s Ebglyss recommended by NICE for NHS atopic dermatitis patients

FHS
July 13, 2024
4:21 am

Almirall S.A., a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.

Using deep brain stimulation to map dysfunctional brain circuits linked to four disorders

Mass General Brigham researchers identified sets of connections that are disrupted and malfunctioning as a consequence of Parkinson’s disease, dystonia, obsessive compulsive disorder and Tourette’s

February 24, 2024

Navigating the Digital Front Door: Overcoming Friction in New Patient Registration

Scott Heatherly, VP of Sales at Amenities Health In today’s fast-paced digital age, traditional healthcare systems are under growing pressure to adapt their digital front-door

June 11, 2024

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens – Biotech Investments

Biophytis / Key word(s): Miscellaneous/Miscellaneous Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens 12-Jun-2024 / 10:11 CET/CEST Biophytis

June 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.